艾萨康唑在儿童癌症患者中的真实世界评估
该队列研究报告2018至2023年荷兰Princess Máxima中心77例儿童(中位年龄8.0岁)使用艾萨康唑的92个疗程,主要用于二线治疗。治疗总体耐受良好,预测暴露量与关键试验一致;低体重儿童需更高按体重剂量才能达到等效暴露,且个体间/个体内变异较大,支持进行治疗药物监测。
要点
- 艾萨康唑在儿童癌症患者中总体耐受良好,暴露量与关键试验一致。
- 低体重儿童需更高按公斤体重剂量才能达到与年长儿等效的暴露。
- 个体间/个体内变异较大,支持开展治疗药物监测。
核心结论
- 艾萨康唑在儿童侵袭性真菌感染治疗中有一席之地,总体耐受良好且暴露与关键试验一致。
- 低体重儿童需更高按体重剂量以达到与年长儿等效的暴露。
- 较大的个体间/个体内变异支持进行治疗药物监测。
研究设计与样本
- 该研究为队列研究,报告2018至2023年荷兰Princess Máxima中心儿童使用艾萨康唑的情况。
- 共纳入77例患者(中位年龄8.0岁),涉及92个治疗疗程。
- 从患者记录中提取临床数据、毒性数据及艾萨康唑血浆浓度,并事后采用非线性混合效应模型估计暴露。
主要发现
- 77例患者中72例为血液系统恶性肿瘤,34/77接受了干细胞移植。
- 中位疗程持续时间为75.5天(IQR,44-144)。
- 29.1%的治疗中止与确认的药物副作用无关。
- 共获得958个浓度,中位Ctrough为3.3 mg/L(范围,0.04-12.6)。
- 患者内变异系数为30.6%(IQR,21.1%-42.8%)。
关键数值与推荐
- 第一周预测暴露量为79.2 mg·h/L(范围,35.2-95.8),81.8%>60 mg·h/L(关键试验的25th百分位数)。
- 体重<18 kg、18-32 kg和≥32 kg患者的中位维持剂量分别为6.4、5.2和4.6 mg/kg/day。
临床怎么用
- 艾萨康唑可作为儿童侵袭性真菌感染的治疗选择,尤其作为二线治疗。
- 低体重儿童应按体重给予更高剂量以达到等效暴露。
- 建议进行治疗药物监测以应对较大的个体间/个体内变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Isavuconazole is widely used in children. It has a favourable safety profile, fewer drug-drug interactions, predictable pharmacokinetics and broad spectrum of action compared with alternative triazoles. OBJECTIVES: To assess its place in therapy in a real-world setting, and investigate the achieved exposure. METHODS: This cohort study reports isavuconazole usage in children between 2018 and 2023 in the Princess Máxima Center, the Netherlands. Clinical data, toxicity data and isavuconazole plasma concentrations were extracted from patient records. Exposure was estimated post hoc using nonlinear mixed-effects modelling. RESULTS: In total, 77 patients (median age 8.0 years) received isavuconazole during 92 episodes. Isavuconazole was primarily prescribed as second-line therapy. Out of 77 patients, 72 had a haematological malignancy and 34/77 underwent stem cell transplantation. Median episode duration was 75.5 (IQR, 44-144) days. Treatment was discontinued in 29.1% unrelated to confirmed drug side effects. 958 concentrations were available. Median Ctrough was 3.3 (range, 0.04-12.6) mg/L. The intra-patient coefficient of variation was 30.6% (IQR, 21.1%-42.8%). Predicted exposure during the first week was 79.2 (range, 35.2-95.8) mg·h/L, 81.8% > 60 mg·h/L, the 25th percentile from a pivotal trial. Median maintenance dosage for patients <18 kg, 18-32 kg and ≥32 kg was 6.4, 5.2 and 4.6 mg/kg/day. CONCLUSION: We think that isavuconazole merits a place for treatment of invasive fungal infections in children. Isavuconazole was generally well tolerated with exposures in line with the pivotal trial. Lower-weight children required higher dosage per kg of bodyweight to achieve equivalent exposures to their older peers. Considerable inter/intra-patient variability supports the need for therapeutic drug monitoring.
引用
- Nijhuis J, Jansen AME, Wolfs TFW, et al. Real-world evaluation of isavuconazole in children with cancer. J Antimicrob Chemother. 2026. PMID: 41562231. doi:10.1093/jac/dkaf485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。